



## Investment Sciences

## Establishing Our Priors

**A key building block for taking an empirical perspective on company fundamentals is our expectations (or priors) for the situations we look at:** Looking at market-relative performance, the expected excess return for a randomly selected stock should be about zero (more or less by definition). But the reality is that we do not pick stocks to pay attention to at random – they come to our attention for a reason.


**Stocks that Barclays fundamental analysts rate differently have had different distributions of returns:** Compared to Equal Weights, Overweights have had higher risk-adjusted returns with similar volatility, while Underweights have had higher volatility but similar risk-adjusted returns.

**Changes in ratings have been discrete events that also signal different return profiles:** Stocks that were upgraded one rating outperformed the market in the subsequent 3 months; stocks that were upgraded two ratings, while more rare, outperformed for 6 months.

**A strategy of buying the upgrades and holding them for 3 months would have outperformed the market since 2003:** Though that performance has been flat to the S&P 500 in recent years, it has continued to outperform the non-technology components of the index.

FIGURE 1

Since 2003, Stocks That Were Upgraded by Barclays Analysts Outperformed Those That Were Downgraded



Source: Thomson, IDC, Barclays Research

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 8.

## MACRO STRATEGY

## Investment Sciences

## Investment Sciences

Ryan Preclaw

+1 212 412 2249

ryan.preclaw@barclays.com

BCI, US

## Empirical Building Blocks

An important building block for systematically combining data analysis with our analysts' knowledge about companies is our baseline (or prior) beliefs about a stock's return distribution. Having that foundation allows us to put the appropriate weight on new data-driven insight, to get a more refined view about potential returns that captures both what we already knew, and what we have learned. Even in situations where combining those insights formally is impractical, we think it remains a useful framework for understanding how much a new piece of information should change our views.

For stocks that are covered by Barclays analysts, a good starting point is to consider how return distributions differ based on those analysts' views. To do that, we use Barclays Equity Research's history of ratings and rating changes. Some key information about this data:

- The database has 7,184 ratings changes, covering 1596 stocks, starting in August 2002<sup>1</sup>.
- We dropped all the events for non-US companies, in order to focus on names that were most appropriately benchmarked against the S&P 500. We also excluded GM, because returns around its bankruptcy filing were throwing off returns aggregations. In the end, we were left with data on 1473 companies.
- Finally, we joined the ratings events with daily returns from IDC and Thomson, and index returns from Bloomberg, to calculate the excess returns (stock return – S&P 500 return) for each covered stock. That measure of excess return is our focus here.

### Excess Returns for Market Weight Stocks Have Been Near Zero, Positive (and Significant) for Overweights, but More Ambiguous for Underweights

When we look at the distributional characteristics of stocks conditioned on their ratings, a few key points stand out:

**Overweights' excess returns have been positive on average**, and statistically significant at the 95% level (Figure 2).

**Equal Weights' mean return is near zero**, though the 95% confidence interval (CI) overlaps substantially with the range for Overweights.

**Underweights' mean excess returns have been positive**, but with very wide confidence intervals. The 95% CI ranges for Underweights is so wide that we can't reject the possibility that their true mean is substantially negative. But we also can't dismiss the possibility that their true expected return is higher than for the Overweights.


**Barclays' decision about whether or not to cover stocks has implications for returns.** Given the average performance profiles of the three covered categories, process of elimination suggests that uncovered stocks must on average be underperformers relative to the S&P 500. Though like covered stocks, there will be both out- and under-performers in the group.

---

<sup>1</sup> On 16th September 2008 Barclays announced the acquisition of Lehman Brothers North American operations. The ratings data prior to that date was Lehman Brothers.

FIGURE 2


**Barclays Overweight Rated-Stocks Have Had Statistically Significant Positive Excess Returns...**



Source: Thomson QAD, IDC, Barclays Research

FIGURE 3

**...Underweights are consistently more volatile than Equal Weights or Overweights**




Source: QAD, IDC, Barclays Research. Note: standard error for second moment was estimated via a bootstrapping method.

Expected returns are important for investors, but so are risks. And here, we see more clearly the difference in the distribution of returns for Underweight-rated stocks and the other two ratings categories. As Figure 3 shows, there is substantial overlap in confidence intervals for the volatility of Equal Weight and Overweight stocks. By contrast, Underweight-rated stocks were about 25% more volatile than either of the other categories, and that difference was statistically significant (in the sense that there is no overlap in the CI ranges). So even though we can't be (statistically) certain that Underweights are performance worse than Overweights, they have been dependably (statistically) more volatile. For clients making stock selections in a risk-adjusted framework, that difference is critical.

FIGURE 4

**Relative to Equal Weights, Overweights Have Had More Return for Similar Risk, Underweights Have Had More Risk for Similar Returns**



Source: Thomson QAD, IDC, Barclays Research

These facts together also give us perspective in how to establish an empirical prior distribution for the stocks rated by Barclays analysts, which is especially clear when we frame it in a risk and risk-adjusted return context (Figure 4). Equal Weights have an average excess return close to zero, Overweights have similar risk profile but higher expected


returns, and Underweights have a similar central expectation for risk-adjusted returns, but with higher risk.

### Different Ratings Changes Followed Different Return Paths

The rating levels are not the only piece of information we want to consider with regard to how stock returns might be different as a function of analyst views. The act of changing ratings provides us with discrete events to analyze. We looked on four basic kinds of ratings events: One- and two-notch upgrades, and one- and two-notch downgrades.


To evaluate how we should adjust expectations based on a ratings change event, we created an event-study dataset. We took every ratings change that affected the stocks in the set above. Then, we generated returns series for each, starting from six months prior to the change, to six months after. The cumulative return averages to each horizon is in Figures 5 and 6, with the “zero” point in the center the closing price on the day the rating change was released.

FIGURE 5  
Mean Cumulative Excess Return



Source: Thomson QAD, IDC, Barclays Research

FIGURE 6  
Median Cumulative Excess Return



Source: Thomson QAD, IDC, Barclays Research

There are some interesting things to note about returns around ratings changes:

**Stocks tend to be falling into downgrades and rising into upgrades.** Within that pattern, it's interesting that the one-notch upgrades tend to be modestly weak in the leadup to the upgrade, then jump just prior to the change.

**Two-rating upgrades are the most reliable outperformers.** They generate positive excess returns even out to 6 months after ratings changes.


**Two-rating downgrades also have positive performance after the rating change, although the differences between mean and median show that it is also volatile.** But they also have the most extreme downward performance into the rating change. One way to think about them may be that the ratings change tends to happen around the culmination of very bad events, so that some stocks rebound shortly thereafter. Two-rating downgrades are also rare, with fewer than 10 a year in our dataset.

We use a regression to estimate the performance of stocks around each rating change, as show in Figure 6 (note that we use a generalized linear model, rather than ordinary least squares, because the returns are not normally distributed). At a three-month horizon, excess returns are positive and statistically significant at the 95% level for both one-notch upgrades (+1.5%) and two-notch (+4.0%) *downgrades*. Two-notch upgrades (+4.5%) are

close enough to statistically valid (significant at the 94.7% level) that in practical terms they appear to be valid. Their relatively high standard error is likely because they are the least common ratings change event, representing only 2.2% of the examples.

FIGURE 7

**Upgrades Generate Statistically Significant Outperformance Over a 90-Day Horizon, One-Notch Downgrades are Statistically Indistinguishable from Zero, and 2-Notch Downgrades are Big Outperformers**



Source: Thomson QAD, IDC, Barclays Research

Returning to the idea of updating our views on a name to capture analyst views, that means that the time since the most recent ratings change will also influence our view on potential returns.


### Systematically Buying Upgrades Could Inform an Alpha-Capture Strategy

If our result that analyst upgrades are statistically significant and positive, it would imply that we should be able to create an alpha-capture style strategy using them that outperforms the S&P 500 benchmark we used. Although there are probably too few two-rating upgrades for a dedicated strategy (Figure 8), we generally have plenty of one-rating upgrades (Figure 9) to work with at any given time.

FIGURE 8

**Barclays Fundamental Researchers Typically Have 3 Stocks Within 3 Months of a Two-Rating Upgrade...**

Two -Rating Upgrades  
in Trailing 6m Period




Source: Barclays Research

FIGURE 9

**...But The Number of Stocks Within 3 Months of an One-Rating Upgrade Has Averaged Closer to 40 Since 2013**

One-Rating Upgrades  
in Trailing 3m Period




Source: Barclays Research

To conduct a simplified backtest, we constructed an equal-weighted portfolio of every name upgraded two-rating in the past 6 months, and every name upgraded one-rating in the past 3 months. We keep things very simple: no transaction costs, and assume daily rebalancing back to equal weight.

FIGURE 10

**Alpha Capture –Style Strategy Would Have Outperformed S&P 500 Since 2003...**

Cum. Non-Compounded  
Total Return




Source: Thomson QAD, IDC, Bloomberg, Barclays Research

FIGURE 11

**...Though The Excess Return Generation Has Been Lower Since 2014**

Total Return




Source: Thomson QAD, IDC, Bloomberg, Barclays Research

Figure 10 shows the cumulative (non-compounded) total return vs. S&P 500 and the S&P 500 Equal Weighted indices, and Figure 11 shows the annual performance (with compounding). Although simplified, a strategy of owning an equal-weighted portfolio of Barclays analyst upgrades would have returned more than the S&P 500 since 2003. It would also have outperformed on a risk-adjusted basis, with an information ratio of 0.97. There are a few notes of caution of course; the first being that this is not a formally constructed backtest, so does not include transaction costs or estimates for market impact.

The strategy would also have performed less well in the past four years. The reasons for that are unclear, though some of it is likely attributable to the concentrated contribution of S&P gains from technology companies. Any equal-weighted strategy is likely to underperform in a period when gains are concentrated in a few stocks, and as Figure 13 demonstrates, the performance has exceeded that of the non-technology components of the S&P 500.

FIGURE 12

**An Alpha Capture Style Strategy Would Only Have Matched the S&P 500 Since 2013, But Would Have Returned More Than S&P 500 Ex. Tech and Equal Weighted Indices**



Source: Thomson QAD, IDC, Bloomberg, Barclays Research

## ANALYST(S) CERTIFICATION(S):

I, Ryan Pclaw, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

## IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

### Availability of Disclosures:

Where any companies are the subject of this research report, for current important disclosures regarding those companies please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities, the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

### Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

### Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

### Stock Rating

**Overweight** - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Equal Weight** - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Underweight** - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Rating Suspended** - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

### Industry View

**Positive** - industry coverage universe fundamentals/valuations are improving.

**Neutral** - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

**Negative** - industry coverage universe fundamentals/valuations are deteriorating.

### Distribution of Ratings:

Barclays Equity Research has 1536 companies under coverage.

44% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 58% of companies with this rating are investment banking clients of the Firm; 75% of the issuers with this rating have received financial services from the Firm.

38% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 47% of companies with this rating are investment banking clients of the Firm; 67% of the issuers with this rating have received financial services from the Firm.



## IMPORTANT DISCLOSURES CONTINUED

Firm.

15% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 36% of companies with this rating are investment banking clients of the Firm; 67% of the issuers with this rating have received financial services from the Firm.

### Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

### Top Picks:

Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. To view the current list of Top Picks, go to the Top Picks page on Barclays Live (<https://live.barcap.com/go/keyword/TopPicks>).

To see a list of companies that comprise a particular industry coverage universe, please go to <https://publicresearch.barclays.com>.

### Types of investment recommendations produced by Barclays Equity Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.

### Disclosure of other investment recommendations produced by Barclays Equity Research:

Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

### Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

## DISCLAIMER:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC ([www.iiroc.ca](http://www.iiroc.ca)), and a Member of the Canadian Investor Protection Fund (CIPF).

All Barclays research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No:

+91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by either Barclays Bank PLC, Barclays Capital Inc., Barclays Capital Securities Limited or Barclays Capital Asia Limited. None of Barclays Bank PLC, nor any of the other referenced Barclays group entities, hold an Australian financial services licence and instead they each rely on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2018). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

